It is not an easy task to change pharma’s market approach. Ever since 2002, product oriented detaling has been grown into a firmly standardized routine for all pharma companies. But markets have changed in the meantime and have become different by structure, reimbursement and price. Avoiding the commodity trap is challenging. Here is a short review of how we changed in the Netherlands and put customer first.
Pharma’s promotion is ever more built on edetailing. Often it is a digital transcription of what has been done in paper brochures. Much more benefits can be gained when one really transfers to digital detailing. See here an excerpt of our training done in Moscow for the Russian situation.
In the Dutch pharmaceutical market several developments have influenced prescription policies of GPs. The liberalization of the health care market in the Netherlands has led the health care insurance companies to challenge GPs on their policies on treatment of chronic conditions.
These health care groups¹ went also on to develop prescription policies, endorsed to do so by extra reimbursement schemes from the part of the insurance companies.
In an early stage, we have acknowledged the potential impact of these health care groups on actual prescription routines. With the pharmaceutical company that we worked with, we configured an account team that would focus specifically on these groups.